Amphastar Pharmaceuticals (AMPH) ROE: History & Chart

Amphastar Pharmaceuticals, Inc.(AMPH)

Drug Manufacturers - Specialty & Generic · Rancho Cucamonga, CA

$25.13-0.24 (-0.95%)

Delayed quote: Oct 6, 2026, 10:35 AM EDT

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Rancho Cucamonga, CA

1,976 employees

www.amphastar.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Yongfeng Zhang

View full financials

AMPH Return on Equity (ROE) Metrics

RETURN ON EQUITY (ROE)

10.23%

RETURN ON EQUITY (ROE) AVG TTM

13.01%

RETURN ON EQUITY (ROE) AVG 3Y

18.10%

RETURN ON EQUITY (ROE) AVG 5Y

17.12%

RETURN ON EQUITY (ROE) AVG 10Y

10.11%

RETURN ON EQUITY (ROE) AVG 15Y

N/A

RETURN ON EQUITY (ROE) AVG 20Y

N/A

CURRENT VS TTM AVG

-21.42%

CURRENT VS 3Y AVG

-43.50%

CURRENT VS 5Y AVG

-40.26%

CURRENT VS 10Y AVG

+1.09%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

-40.09%

median of 523 covered companies

CURRENT VS SECTOR MEDIAN

+125.51%

vs the sector median at left

NAME	MARKET CAP	RETURN ON EQUITY (ROE)	TTM	3Y	5Y
Amphastar Pharmaceuticals, Inc. (AMPH)	$1.11B	10.23%	13.01%	18.10%	17.12%
Harrow Health, Inc. (HROW)vs ›	$1.12B	-244.91%	-17.45%	-30.16%	-48.76%
IRadimed Corporation (IRMD)vs ›	$1.09B	22.66%	22.95%	21.85%	17.09%
Bicara Therapeutics Inc. Common Stock (BCAX)vs ›	$1.09B	-39.54%	-24.09%	36.77%	36.77%
Kardigan, Inc. (KARD)vs ›	$1.12B	N/A	76.67%	76.67%	76.67%
Avalyn Pharma Inc. Common Stock (AVLN)vs ›	$1.14B	N/A	35.70%	35.70%	35.70%
Damora Therapeutics, Inc. (DMRA)vs ›	$1.13B	-50.93%	-117.72%	-113.46%	-86.51%
GoodRx Holdings, Inc. (GDRX)vs ›	$1.16B	2.51%	3.60%	0.50%	-7.05%
Castle Biosciences, Inc. (CSTL)vs ›	$1.05B	-4.13%	-0.56%	-8.16%	-7.12%
Teladoc Health, Inc. (TDOC)vs ›	$1.05B	-13.54%	-40.81%	-170.75%	-114.78%

NAME

MARKET CAP

RETURN ON EQUITY (ROE)

TTM

Amphastar Pharmaceuticals, Inc. (AMPH)

$1.11B

10.23%

13.01%

18.10%

17.12%

Harrow Health, Inc. (HROW)vs ›

$1.12B

-244.91%

-17.45%

-30.16%

-48.76%

IRadimed Corporation (IRMD)vs ›

$1.09B

22.66%

22.95%

21.85%

17.09%

Bicara Therapeutics Inc. Common Stock (BCAX)vs ›

$1.09B

-39.54%

-24.09%

36.77%

Kardigan, Inc. (KARD)vs ›

$1.12B

N/A

76.67%

Avalyn Pharma Inc. Common Stock (AVLN)vs ›

$1.14B

N/A

35.70%

Damora Therapeutics, Inc. (DMRA)vs ›

$1.13B

-50.93%

-117.72%

-113.46%

-86.51%

GoodRx Holdings, Inc. (GDRX)vs ›

$1.16B

2.51%

3.60%

0.50%

-7.05%

Castle Biosciences, Inc. (CSTL)vs ›

$1.05B

-4.13%

-0.56%

-8.16%

-7.12%

Teladoc Health, Inc. (TDOC)vs ›

$1.05B

-13.54%

-40.81%

-170.75%

-114.78%

Return on Equity (ROE) FAQ

What is the return on equity (ROE) for Amphastar Pharmaceuticals, Inc. (AMPH)?

The return on equity (ROE) for AMPH stock is 10.23%.

Is Amphastar Pharmaceuticals, Inc.'s return on equity (ROE) high or low?

The return on equity (ROE) of 10.23% is 40% below its 5-year average of 17.12%, around the middle of its 5-year range (2.48%–23.34%).

What is the TTM average return on equity (ROE) for Amphastar Pharmaceuticals, Inc. (AMPH)?

The TTM average return on equity (ROE) for AMPH stock is 13.01%.

What is the 3Y average return on equity (ROE) for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 3Y average return on equity (ROE) for AMPH stock is 18.10%.

What is the 5Y average return on equity (ROE) for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 5Y average return on equity (ROE) for AMPH stock is 17.12%.

What is the 10Y average return on equity (ROE) for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 10Y average return on equity (ROE) for AMPH stock is 10.11%.

DATE	RETURN ON EQUITY (ROE)
2026-06-30	10.23%
2026-03-31	10.24%
2025-12-31	12.44%
2025-09-30	14.37%
2025-06-30	17.78%
2025-03-31	18.85%
2024-12-31	21.78%
2024-09-30	21.67%
2024-06-30	23.34%
2024-03-31	23.01%
2023-12-31	21.51%
2023-09-30	22.73%
2023-06-30	17.30%
2023-03-31	16.98%
2022-12-31	17.29%
2022-09-30	15.29%
2022-06-30	18.21%
2022-03-31	16.96%
2021-12-31	13.94%
2021-09-30	8.39%
2021-06-30	2.48%
2021-03-31	0.62%
2020-12-31	0.35%
2020-09-30	1.64%
2020-06-30	1.02%
2020-03-31	13.78%
2019-12-31	12.83%
2019-09-30	13.31%
2019-06-30	13.64%
2019-03-31	0.70%
2018-12-31	-1.74%
2018-09-30	-1.93%
2018-06-30	-2.62%
2018-03-31	-1.11%
2017-12-31	1.34%
2017-09-30	0.09%
2017-06-30	1.20%
2017-03-31	2.74%
2016-12-31	3.20%
2016-09-30	6.33%
2016-06-30	4.52%
2016-03-31	0.12%
2015-12-31	-0.94%
2015-09-30	-4.52%
2015-06-30	-5.33%
2015-03-31	-3.49%
2014-12-31	-3.80%
2014-09-30	-2.24%
2014-06-30	-0.39%
2014-03-31	3.13%
2013-12-31	4.72%
2013-09-30	5.79%

DATE

RETURN ON EQUITY (ROE)

2026-06-30

10.23%

2026-03-31

10.24%

2025-12-31

12.44%

2025-09-30

14.37%

2025-06-30

17.78%

2025-03-31

18.85%

2024-12-31

21.78%

2024-09-30

21.67%

2024-06-30

23.34%

2024-03-31

23.01%

2023-12-31

21.51%

2023-09-30

22.73%

2023-06-30

17.30%

2023-03-31

16.98%

2022-12-31

17.29%

2022-09-30

15.29%

2022-06-30

18.21%

2022-03-31

16.96%

2021-12-31

13.94%

2021-09-30

8.39%

2021-06-30

2.48%

2021-03-31

0.62%

2020-12-31

0.35%

2020-09-30

1.64%

2020-06-30

1.02%

2020-03-31

13.78%

2019-12-31

12.83%

2019-09-30

13.31%

2019-06-30

13.64%

2019-03-31

0.70%

2018-12-31

-1.74%

2018-09-30

-1.93%

2018-06-30

-2.62%

2018-03-31

-1.11%

2017-12-31

1.34%

2017-09-30

0.09%

2017-06-30

1.20%

2017-03-31

2.74%

2016-12-31

3.20%

2016-09-30

6.33%

2016-06-30

4.52%

2016-03-31

0.12%

2015-12-31

-0.94%

2015-09-30

-4.52%

2015-06-30

-5.33%

2015-03-31

-3.49%

2014-12-31

-3.80%

2014-09-30

-2.24%

2014-06-30

-0.39%

2014-03-31

3.13%

2013-12-31

4.72%

2013-09-30

5.79%

Return on Equity (ROE): 10.23%

AMPH Return on Equity (ROE)

AMPH Average Return on Equity (ROE) Chart

AMPH Current vs Average Return on Equity (ROE) Chart

AMPH Return on Equity (ROE) Metrics

AMPH Competitors' Return on Equity (ROE)

Return Analysis

Return on Equity (ROE) Formula & Definition

Return on Equity (ROE) FAQ

AMPH Return on Equity (ROE) History

Related Metrics